

PHARMEDIC

PHAMACEUTICAL MEDICINAL JOIN STOCK

367 Nguyen Trai street, Cau Ong Lanh Ward, HCM city

Tax code: 0300483037

FINANCIAL REPORT

3TH QUARTER 2026

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

STATEMENT OF FINANCIAL POSITION

As at 30th September 2026

Currency: VND

	Code	Notes	Ending balance of period	Beginning balance
1	2	3	4	5
ASSETS				
A. CURRENT ASSETS AND SHORT-TERM INVESTMENTS	100		261.538.331.951	219.575.579.955
I. Cash and cash equivalents	110	V.1	7.192.636.978	40.564.104.864
1. Cash	111		7.192.636.978	40.564.104.864
2. Cash equivalents	112		-	-
II. Short-term financial investments	120	V.2	500.000.000	500.000.000
3. Held-to-maturity investments	123		500.000.000	500.000.000
III. Accounts receivable	130		107.412.756.447	66.222.733.916
1. Short-term trade receivables	131	V.3	55.123.165.122	34.720.871.572
2. Short-term advance payments to suppliers	132	V.4	50.983.340.305	31.775.158.531
3. Phải thu nội bộ ngắn hạn	133			
4. Phải thu theo tiến độ kế hoạch hợp đồng xây dựng	134			
5. Other short-term receivables	135	V.5	2.411.908.074	781.298.114
6. Provisions for doubtful debts (*)	136		(1.105.657.054)	(1.054.594.301)
7. Deficit assets for treatment	137			
IV. Inventories	140	V.6	142.500.310.324	103.930.108.712
1. Inventories	141		142.500.310.324	103.930.108.712
2. Provision for obsolete inventory (*)	142			
V. Short-term biological assets	150		-	-
VI. Other current assets	160		3.932.628.202	8.358.632.463
1. Short-term livestock for one-time product harvest	161	V.9	3.851.293.360	3.563.540.430
2. VAT deductible	162		81.334.842	4.795.092.033
3. Tax receivables	163			-
4. Other current assets	165		-	-
B - FIXED ASSETS AND LONG-TERM INVESTMENTS	200		137.239.691.244	125.848.483.770
I. Long-term receivables	210		-	-
II. Fixed assets	220	V.7	112.124.402.795	93.214.840.011
1. Tangible fixed assets	221		97.442.275.788	91.217.110.307
- Historical cost	222		309.639.839.064	289.180.699.098
- Accumulated depreciation (*)	223		(212.197.563.276)	(197.963.588.791)
2. Finance lease fixed assets	224		-	-
- Historical cost	225			
- Accumulated depreciation (*)	226			
3. Intangible fixed assets	227	V.8	14.682.127.007	1.997.729.704
- Historical cost	228		21.587.764.909	8.057.764.909
- Accumulated amortization (*)	229		(6.905.637.902)	(6.060.035.205)
III. Long-term biological assets	230		-	-
IV. Investment Properties	240		-	-
- Historical cost	241			
- Accumulated depreciation (*)	242			

	Code	Notes	Ending balance of period	Beginning balance
1	2	3	4	5
V. Non-current unfinished assets	250		158.189.000	2.418.130.548
1. Long-term work-in-process	251			
2. Construction-in-progress	252		158.189.000	2.418.130.548
V. Long-term financial investments	260		-	-
VI. Other non-current assets	270		24.957.099.449	30.215.513.211
1. Long-term deferred expenses	271	V.10	24.957.099.449	30.215.513.211
TOTAL ASSETS (280 = 100 + 200)	280		398.778.023.195	345.424.063.725
RESOURCES				
C - LIABILITIES	300		147.834.428.156	104.568.735.717
I. Current liabilities	310		147.834.428.156	104.568.735.717
1. Short-term trade payables	311	V.12	29.182.071.102	28.534.924.569
2. Short-term advance payments from customers	312	V.13	1.658.781.498	1.940.919.537
3. Dividends and profits payable	313	V.14	14.071.759.618	15.240.981.474
4. Tax and statutory obligations	314	V.15	10.575.869.501	8.065.664.348
5. Payables to employees	315		24.031.462.022	38.343.369.723
6. Short-term accruals	316			
7. Short-term inter-company payables	317			
8. Construction contractor payables based on agreed progress billings	318			
9. Short-term unearned revenue	319			
10. Other short-term payables	320		987.925.437	561.441.445
11. Short-term finance lease loans and liabilities	321	V.11	59.362.154.705	181.005.840
12. Provisions for short-term payables	322			4.318.000.000
13. Bonus and welfare funds	323	V.17	7.964.404.273	7.382.428.781
14. Price stabilization fund	324			
15. Government bond repurchase transaction	325			
II. Non-current liabilities	330		-	-
D - OWNERS' EQUITY	400	V.18	250.943.595.039	240.855.328.008
1. Owners' invested equity	411		93.325.730.000	93.325.730.000
- Common stocks with voting rights	411a		93.325.730.000	93.325.730.000
- Preferred stocks	411b			
2. Surplus of share capital	412		972.972.000	972.972.000
3. Bond conversion option	413			
4. Other capital of the owner	414			
5. Treasury stock (*)	415			
6. Asset revaluation differences	416			
7. Exchange rate differences	417			
8. Development and investment funds	418			93.250.277.906
9. Other funds of the owner's capital	419			
10. Undistributed earnings after tax	420		156.644.893.039	53.306.348.102
- Accumulated undistributed earnings after tax to the end of previous year	420a		112.346.570.006	340.988.541
- Accumulated undistributed earnings after tax in current year	420b		44.298.323.033	52.965.359.561
TOTAL RESOURCES (440 = 300 + 400)	440		398.778.023.195	345.424.063.725

Prepared by


Trần Mạnh Hùng

Chief Accountant

Nguyễn Diệu Lê
NGUYỄN DIỆU LÊ

Approved 15th October 2026

General Director



PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

INCOME STATEMENT


As at 30th September 2026


Currency: VND

ITEMS	Code	Notes	1rd Quarter of current year	1rd Quarter of previous year	Accumulated from the beginning of year to the end of this quarter	
					Current year	Previous year
1. Revenues from sale of goods and rendering of services	01	VI.1	147.823.554.266	127.528.260.802	409.753.423.702	385.483.770.019
2. Revenue deductions	02	VI.2	2.213.805.246	1.009.138.000	6.472.753.199	1.041.489.722
3. Net revenues from sale of goods and rendering of services	10	VI.3	145.609.749.020	126.519.122.802	403.280.670.503	384.442.280.297
4. Cost of goods sold	11	VI.4	80.122.627.878	73.486.214.101	226.817.201.835	220.144.409.554
5. Gross profit from sale of goods and rendering of services	20		65.487.121.142	53.032.908.701	176.463.468.668	164.297.870.743
6. Profit/loss from the liquidation of investment properties	21					
7. Income from financial activities	22	VI.5	86.559.291	913.086.555	278.884.142	3.816.128.484
8. Expenses from financial activities	23	VI.6	1.548.721.395	259.726.027	3.522.918.855	302.465.753
In which: Interest expenses	24		1.548.721.394	259.726.027	3.522.918.853	259.726.027
9. Selling expenses	25	VI.7	19.430.516.576	13.015.745.834	53.271.849.535	42.493.001.026
10. General & administration expenses	26	VI.8	16.958.600.678	16.450.588.099	46.809.726.669	45.331.066.153
11. Net profit/(loss) from operating activities	30		27.635.841.784	24.219.935.296	73.137.857.751	79.987.466.295
12. Other income	31	VI.9	127.343.414	5.869.758	201.610.521	715.417.071
13. Other expenses	32	VI.10	50.053.925	-	126.489.481	92.820.802
14. Other profit	40		77.289.489	5.869.758	75.121.040	622.596.269
15. Total pre-tax accounting profit	50		27.713.131.273	24.225.805.054	73.212.978.791	80.610.062.564
16. Current Corporate Income tax expenses	51	VI.11	5.542.626.255	4.845.161.011	14.693.655.758	16.167.192.513
17. Deferred Corporate Income tax expenses	52		-	-	-	-
18. Profit/(loss) after corporate income tax	60		22.170.505.018	19.380.644.043	58.519.323.033	64.442.870.051
19. Gains on stock (*)	70	VI.12	1.734	1.516	4.577	5.041
20. Declining returns on stocks (*)	71		1.734	1.516	4.577	5.041

Prepared by

Chief Accountant


Trần Mạnh Hùng


NGUYỄN DIỆU LÊ

Báo cáo này phải được đọc kèm với Thuyết minh báo cáo tài chính



Approved: 15th October 2026

General Director


DS. LÊ VIỆT HÙNG

STATEMENT OF CASH FLOW

As at 30th September 2026

(As per Indirect Method)

Currency: VND

ITEMS	Code	Notes	Accumulated from the beginning of year to the end of this quarter	
			Current year	Previous year
I. Cash flows from operating activities				
1. Net profit/(loss) before tax	01		73.212.978.791	80.610.062.564
2. Adjustments for :			18.653.558.790	4.513.921.788
Depreciation and amortisation	02	V.7&V.8	15.079.577.182	8.273.581.070
Provisions	03		51.062.753	39.280.106
Exchange rate gains and losses resulting from the revaluation of monetary items denominated in foreign currencies.	04		-	-
Profit and loss from investment and financial activities	05		-	(4.101.405.141)
Interest expense	06		3.522.918.855	302.465.753
3. Operating income/(loss) before changes in working capital	08		91.866.537.581	85.123.984.352
(Increase) / decrease in receivables	9		(36.527.328.093)	(49.174.220.084)
(Increase)/decrease in inventory	10		(38.570.201.612)	(44.154.496.846)
Increase/(decrease) in payables (excluding interest payable, PIT payables)	11		(4.864.162.124)	45.033.347.819
Increase or decrease in deferred expenses	12		4.862.642.313	(9.548.259.925)
Increase or decrease in trading securities	13		-	-
Interest paid	14		(3.522.918.855)	-
Corporate income tax paid	15	V.15	(15.559.671.718)	(12.679.568.447)
Other cash inflows from operating activities	16		-	-
Other cash outflows from operating activities	17		(16.454.304.938)	(21.410.338.577)
Net cash inflows/(outflows) from operating activities	20		(18.769.407.446)	(6.809.551.708)
II. Cash flows from investing activities				
1. Purchase of fixed assets and other long-term assets	21		(41.214.731.365)	(70.622.091.192)
2. Proceeds from disposals of fixed assets and other long-term assets	22		-	664.545.455
3. of other entities	23		-	(111.500.000.000)
4. other entities	24		-	252.000.000.000
5. Payments for investments in other entities	25		-	-
6. Proceeds from sales of investments in other entities	26		-	-
7. Interest and dividends received	27		-	5.964.355.574
Net cash inflows(outflows) from investing activities	30		(41.214.731.365)	76.506.809.837
III. Cash flows from financing activities				
1. Proceeds from issue of stocks, capital contribution of the owner	31		-	-
2. Capital redemption of the owners, the acquisition of issued stocks	32		-	-
3. Money received from borrowing	33	V.11	127.832.185.204	-
4. Repayments of borrowing principal	34		(68.651.036.339)	-
5. Repayments of finance lease principal	35		-	-
6. Dividends, gains paid to the owner	36		(32.568.477.940)	(97.923.458.344)
Net cash inflows/(outflows) from financing activities	40		26.612.670.925	(97.923.458.344)
Net cash inflows/(outflows)	50		(33.371.467.886)	(28.226.200.215)
Cash and cash equivalents at the beginning of the year	60		40.564.104.864	60.084.311.574
Impact of exchange rate fluctuation	61		-	-
Cash and cash equivalents at the end of the year (70=50+60+61)	70	V.10	7.192.636.978	31.858.111.359

Prepared by

Chief Accountant

Approve, 15th October 2026

General Director

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

NOTES TO THE FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

These notes form an integral part of and should be read in conjunction with the Financial Statements for the nine-month period ended 30th September 2026 of Pharmedic Pharmaceutical Medicinal Joint Stock Company (hereafter, referred to as “the Company”).

I. OPERATION FEATURES

1. Forms of ownership

Joint stock company.

Pharmedic Pharmaceutical Medicinal Joint Stock Company (abbreviation is: PHARMEDIC JSC) was transferred from Pharmaceutical Medicinal Public Private Joint Venture Enterprise to joint stock company in accordance with the Decision No. 4261/QĐ-UB date 13th August 1997 of the People's Committee of Ho Chi Minh city. The Business Registration Certificate No. 064075 dated 09th December 1997 granted by the Department of Planning and Investment of Ho Chi Minh city and subsequent license changes with the latest change on 04th June 2024 to change the Company representative.

Charter capital according to the Business Registration Certificate is VND 93,325,730,000 as follows:

Shareholders	As at 30th June 2026		As at 01st January 2026	
	Amount (VND)	Proportion (%)	Amount (VND)	Proportion (%)
Saigon Pharmaceutical Company Limited -	40.543.090.000	43,44	40.543.090.000	43,44
Representative of State capital				
Other shareholders	<u>52.782.640.000</u>	<u>56,56</u>	<u>52.782.640.000</u>	<u>56,56</u>
Total	93.325.730.000	100	93.325.730.000	100

2. Lines of business

Production and trading of pharmaceuticals

3. Ngành nghề kinh doanh

- Production and trading of pharmaceuticals, medicinal materials, cosmetics, medical supplies and other products in the medical industry;
- Joint ventures and associations with domestic and foreign organizations and individuals to process a number of raw materials (mainly from medicinal herbs to produce some traditional products);
- Printing and pressing plastic, aluminum and paper packaging;
- Production and trading of chemicals (except highly toxic chemicals), insecticidal and antibacterial products used in the household and medical fields (not produced at the headquarters).
- Other business support service activities n.e.c, details: Joint ventures and associations with domestic and foreign individuals.
- Retail sale of medicines, medical equipment, cosmetics and hygiene supplies in specialized stores, details: Retail sale of medicines, medical equipment, medical supplies and cosmetics.
- Manufacture of other food products n.e.c, details: Production of functional foods
- Technical testing and analysis, details: Storage services and medicine testing services.

4. Normal business and production cycle

The Company's normal business and production cycle is within 12 months.

5. Đặc điểm hoạt động của Công ty trong năm có ảnh hưởng đến Báo cáo tài chính tổng hợp

Revenue in current year increased by 4,9% compared to previous year due to higher selling prices. However, during the year, the Company has settled term deposit contracts, so income from financial activities in current year decreased significantly compared to previous year. In addition, the Company expanded its business scale (opened a branch in Hanoi), so costs from initial operating activities increased compared to previous year. From the above factors have led to pre-tax accounting profit increased by 9,2% compared to previous year.

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

7. Nhân viên

As at 30st September 2026, there are 494 employees who are working at the Company (there were 535 employees at the beginning of

II. ACCOUNTING PERIOD, AND REPORTING CURRENCY

1. The Company's fiscal year

The fiscal year starts on 01st January and ends on 31st December of each calendar year.

2. Reporting currency and methods of foreign currency translation

The standard currency unit used is Vietnam Dong (VND) because the Company uses the main accounting currency unit which is Vietnam Dong (VND) for receipts and payments.

III. ADOPTED ACCOUNTING REGIME AND STANDARDS

1. Applicable accounting regime

The Company has applied the Accounting Standards and the Vietnamese Corporate Accounting System in accordance with the Circular No. 99/2025/TT-BTC dated 27nd October 2025 as well as circulars guidance on implementing the accounting standards of the Ministry of Finance in the preparation and presentation of the Financial statements.

Whereby, the accompanying financial statements, Income Statement, Statement of Cash Flows and Notes to the Financial Statements for the fiscal year and the use of this report is not intended for subjects who are not provided information on the procedures and principles and accounting practices in Vietnam, as well as not intentionally presented the financial position, the business results and the cash flows under the procedures and principles and accounting practices widely accepted in other countries and territories outside Vietnam.

2. Statement on the compliance with the Vietnamese accounting regime and standards

We, the Board of Directors of Pharmedic Pharmaceutical Medicinal Joint Stock Company ensure to follow all the requirements of the accounting standards and the Vietnamese Corporate accounting system promulgating together with the Circular No. 99/2025/TT-BTC dated 27nd October 2025 as well as circulars guidance on implementing the accounting standards of the Ministry of Finance in the preparation of the Financial statements.

IV. ADOPTED ACCOUNTING POLICIES

1 Basic for preparing the aggregated Financial statements

The aggregated Financial statements are prepared based on accrual accounting (excluding information related to the cash flows).

2. Cash and cash equivalents

Cash includes cash on hand, call deposits and cash in transit, monetary gold.

Cash equivalents is the short-term securities of which the due dates can not exceed 3 (three) months from the dates of the investments and the convertibility into cash is easy, and which do not have a lot of risks in the conversion into cash.

3. Financial investments

Held-to-maturity investments

The investments are classified as held-to-maturity if the Company has both the ability and the intention to hold to maturity. Held-to-maturity investments include: term deposits (including treasury bills, promissory note) bonds, preferred stocks which the issuance party is obligated to repurchase at a specific time in the future and held-to-maturity loans for the purpose of collecting interest periodically and other held-to-maturity investments.

Principles for determining held-to-maturity investments are initially recognized at the historical costs include purchase price and expenses related to investments transactions. After initial recognition, these investments are recognized at recoverable amount. Interest income on held-to-maturity investments after the date of acquisition are recognized in Income Statement on the basis of accrual. Interest enjoyed before the Company held is deducted against the historical cost as at the date of acquisition.

When there is certainly evidence shows part of or the entire investment may not be recoverable and the loss can be determined reliably, the loss is recognized in Expenses from financial activities in year and direct reduction of investment value.

4. Receivables

Doubtful receivables are presented by book value subtracting the provisions for doubtful receivables.

Receivables are classified as trade receivables and other receivables comply with the following principles:

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

- Trade receivables reflect the commercial elements arising from selling - purchasing transactions between the Company and the buyer is an independent entity, include receivables from export sales under entrusted others.
- Other receivables reflect the non-commercial elements, unrelated to selling - purchasing transactions.

Provision for doubtful receivables: are prepared for each doubtful debt based on the overdue debts or the estimated losses which may arise.

Increase/Decrease in the balance of provisions for doubtful receivables must be made as at the accounting period ended and are recognized in the general & administration expenses.

5. Inventories

Inventories are recognized at the lower of their historical costs or their net realizable values.

Historical costs of inventories are determined as follows:

- Raw materials, goods: including the acquisition cost and other direct related expenses arising to obtain inventory in current status and place.
- Finished goods: including the cost of direct materials, direct labor and related factory overhead cost are allocated based on normal capacity.
- Work-in-process: including only the costs of main raw materials, direct labor and general production costs.

Net realizable values is the estimated selling price of inventory in normal operating cycle except for the estimated costs to complete and necessary to consume them.

The value of inventories are recognized at the weighted average method and recorded at the perpetual method.

Provision for devaluation of inventory is made for each item based on their costs is higher than their net realizable values.

Increase/Decrease in the balance of provision for devaluation of inventory must be made as at 31st December 2025 and are recognized in the cost of goods sold.

6. Prepaid expenses

Prepaid expenses include the actual arising costs but related to the operating results of numerous accounting periods. The Company's prepaid expenses include:

Tools

Expenses on tools being put into use are allocated into expenses in accordance with the straight line method for the maximum period of 3 years.

Repair costs of fixed assets

Repair costs of assets arising once have great value are allocated into expenses in accordance with the straight line method within 3 years.

7. Tangible fixed assets

Tangible fixed assets are determined by the historical costs less (-) accumulated depreciation. Historical costs of tangible fixed assets include all the expenses of the company to have these fixed assets as of the dates they are ready to be put into use. Other expenses incurred subsequent to the initial recognition are included in historical costs of fixed assets only if they certainly bring more economic benefits in the future thanks to the use of these assets. Those which do not meet the above conditions will be recorded into expenses during the period.

When tangible fixed assets are disposed or liquidated, their historical costs and accumulated depreciation are written off, then any profit (or loss) generated from the liquidation is included in the income or the expenses during the period.

Tangible fixed assets are depreciated in line with straight-line method to gradually write off the historical costs of fixed assets over their estimated useful lives. The depreciation years of tangible fixed assets applied are as follows:

Kinds of fixed assets	Years
+ Buildings and structures	05 – 30
+ Machineries and equipments	06 – 10
+ Vehicles, transmissions	06 – 10
+ Management equipments, tools	03 – 08

8. Intangible fixed assets

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Intangible fixed assets are determined by the historical costs less (-) accumulated amortization.

Historical costs of intangible fixed assets include all the expenses of the company to have these fixed assets as of the dates they are ready to be put into use. Other expenses incurred subsequent to the initial recognition are included in expenses during the period only if they attached to the specific intangible fixed asset and bring more economic benefits thanks to the use of these assets.

When intangible fixed assets are disposed or liquidated, their historical costs and accumulated amortization are written off, then any profit (or loss) generated from the liquidation is included in the income or the expenses during the period.

The Company's intangible fixed assets include:

Land-use right

Costs related to computer software programs is not an integral part of the related hardware is capitalized. Historical costs of computer software include all the expenses of the Company to pay until the date the software is put into use. Computer software is amortized in line with straight-line method from 03 to 05 years.

Other intangible fixed assets

Costs related to computer software programs is not an integral part of the related hardware is capitalized. Historical costs of computer software include all the expenses of the Company to pay until the date the software is put into use. Computer software is amortized in line with straight-line method from 03 to 05 years.

Other intangible fixed assets

Other intangible fixed assets is amortized in line with straight-line method to gradually write off the historical costs of fixed assets over their estimated useful lives.

9. Liabilities and accruals

Liabilities and accruals are recognized for payable amounts in the future related to the received goods and services. Accruals are recognized based on the reasonable estimates of the payable amounts.

Payables are classified as trade payables, accruals, payables to employees and other payables comply with the following principles:

- Trade payables reflect the commercial elements arising from purchasing transactions of goods, services, assets and the seller is an independent entity.
- Accruals reflect the payables to the received goods and services from seller or provided to buyer but not yet paid due to do not have invoice or insufficient accounting records and vouchers and payable to employees on sabbatical salary, operating costs must be accrued.
- Payables to employees reflect payables and the payment status to employees for wages, bonus and others belonging to employees' income. The Company makes appropriation of the salary fund according to the Resolution of the Board of Management No. 38/PMC-HĐQT dated 01st August 2014 on salary coefficient rate of 56% on Total revenue minus (-) total expenses without salary.
- Other payables reflect the non-commercial elements, unrelated to selling - purchasing transactions, rendering of services.

10. Owners' equity

Owner's invested equity

Owner's invested equity is recognized according to the shareholders' actual capital.

Surplus of share capital

Surplus of share capital is recognized at differences between issued actual value and the nominal value of stocks when they first issued, supplement issue, differences between re-issued value and the book value of treasury stocks and capital structure of the convertible bonds at maturity. Direct costs related to the issuance of additional stocks and the re-issuance of treasury stocks is reversed on Surplus of share capital.

Other capital of the owner

Other capital is formed by supplementing from business results, revaluation of assets and the remaining value between the fair value of donated, presented, and sponsored assets after deducting taxes payable (if any) related to these assets.

Treasury stocks

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

When repurchasing of stocks by the Company that issued them, the payments including transaction costs are recorded as treasury stocks and reflected as a deduction from owners' equity. When reissuing, differences between the reissue price and the book value of treasury stocks will be recorded into "Surplus of share capital".

11. Profit distribution

Profit after corporate income tax is distributed to shareholders after appropriating for funds in accordance with the Charter of Parent company and subsidiaries as well as regulations and being approved by General Meeting of Shareholders.

Distribution of profits to shareholders is considered non-monetary items in undistributed earnings after tax which can affect the cash flows and ability to pay dividends such as profit from revaluation of the contributed assets, revaluation of monetary items, financial instruments and other non-monetary items.

Dividends are recorded as liabilities when being approved by General Meeting of Shareholders.

12. Recognition of revenues and income

Revenues are recognized when the Company may get economic benefits that can be determined reliably. Revenues are measured at the fair value of received or receivable accounts after deducting trade discounts, sales discounts and sales returns.

Revenues from sale of merchandises (functional foods, cosmetics, ...) and sales of finished pharmaceutical products of all kinds

- Revenues from sale of merchandise, finished goods are recognized when satisfying the following conditions at the same time:
 - Most of risk and benefits associated with the goods ownership are transferred to customers;
 - There are no rights to manage or to control the goods;
 - Revenues can be determined reliably;
 - Getting or will get reliable economic benefits from providing service;
 - Expenses related to providing and completing service can be determined.

Interest

Interest is recognized on an accrual basis, and determined on balance of savings accounts and the actual interest rates for each period.

13. Revenue deductions

Revenue deductions are adjusted reductions of total revenue in year which include sales discounts and sales returns.

14. Cost of goods sold

Cost of goods sold is total cost of goods, production costs of finished goods sold, other expenses are included or recorded reducing in the cost of goods.

15. Expenses from financial activities

Expenses from financial activities are the costs related to financial activities include loss on foreign exchange.

16. Selling expenses and General & administration expenses

Selling expenses and General & administration expenses are all costs related to the process of selling products, goods, rendering of services and general administration expenses of the Company.

17. Transactions in foreign currencies

The transactions in foreign currencies are converted at the actual exchange rates ruling as of the transaction dates. The balances of monetary items in foreign currencies as at 31st December 2025 are converted at the actual exchange rates ruling on this date.

Foreign exchange differences arising during year from transactions in foreign currencies are recognized in income from financial activities or expenses from financial activities. Exchange rate differences due to the revaluation of monetary items in foreign currencies as at 31st December 2025 after offsetting differences of increasing and decreasing are recognized in income from financial activities or expenses from financial activities.

18. Corporate income tax

Corporate income tax expenses include current corporate income tax and deferred corporate income tax.

▪ *Current Corporate income tax*

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Current corporate income tax expense is recognized based on taxable income. Taxable income is different from accounting profit due to the adjustments of temporary differences between tax and accounting figures as well as those of non-taxable or non-deductible income and expenses.

▪ **Deferred Corporate income tax**

Deferred income tax is the amount of corporate income tax payable or refundable due to temporary differences between book values of assets and liabilities serving the preparation of the financial statements and the values for tax purposes. Deferred income tax liabilities are recognized for all the temporary taxable differences. Deferred income tax assets are recorded only when there is an assurance on the availability of taxable income in the future against which the temporarily deductible differences can be used.

Book values of deferred corporate income tax assets are considered at the balance sheet dates and will be reduced to the rates that ensure enough taxable income against which the benefits from a part of or all of the deferred income tax can be used. Deferred corporate income tax assets are not yet recorded in before that will be reconsidered as at the accounting period ended and recorded when being reliably taxable profit to be able to use deferred income tax assets.

Deferred income tax assets and deferred income tax liabilities are determined at the estimated rates to be applied in the year when the assets are recovered or the liabilities are settled based on the effective tax rates as of the balance sheet date. Deferred income tax is recognized in the income statement. In the case that deferred income tax is related to the items of the owner's equity, corporate income tax will be included in the owner's equity of the company.

Deferred income tax assets and deferred income tax liabilities should be offset when:

- The Company has a legal right to implement the offset of current income tax assets and current income tax payable; and
- Those deferred income tax assets and deferred income tax payable related to corporate income tax is administered by the same tax authority
- For the same taxable entity; or
- The Company intends to pay current income tax payable and current income tax assets on the basis of net or recover assets at the same time with the payment of liabilities in each future period when the significant deferred income tax payable or deferred income tax assets to be paid or recovered.

19. Related parties

A party is considered as a related party of the company in case that party is able to control the company or to cause material effects on the financial decisions as well as the operations of the company. A party is also considered a related party of the company in case that party is under common control or significant influence.

In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

20. Segment Reporting

A business segment is a distinguishable component of an enterprise that is engaged in providing an individual product or service or a group of related products or services and that is subject to risks and returns that are different from those of other business segments.

A geographical segment is a distinguishable component of an enterprise that is engaged in providing products or services within a particular economic environment and that is subject to risks and returns that are different from those of components operating in other economic environments.

V. ADDITIONAL INFORMATION FOR ITEMS PRESENTED IN THE FINANCIAL STATEMENT**1. Cash and cash equivalents**

	Ending balance of period		Beginning balance	
	Foreign currencies	VND	Foreign currencies	VND
Cash on hand		609.791.171		562.362.624
Cash in banks		6.582.845.807		40.001.742.240
In which : USD deposits	1.544,18	40.591.997	1.548,58	40.846.895
EURO deposits				
Cash equivalents		-		-

Thuyết minh này là một bộ phận không thể tách rời với Báo cáo tài chính

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

(Term deposits of 3 months or less)		-	-		
Total		7.192.636.978	40.564.104.864		
2. Held-to-maturity investments					
		Ending balance of period	Beginning balance		
(6-month term deposits)		500.000.000	500.000.000		
Total	-	500.000.000	500.000.000		
3. Trade receivables					
		Ending balance of period	Beginning balance		
Sales of products		55.123.165.122	34.720.871.572		
Transferring raw material		-	-		
Total	-	55.123.165.122	34.720.871.572		
4. Advance payments to suppliers					
		Ending balance of period	Beginning balance		
Purchase of materials for production		3.384.142.175	3.527.687.775		
Purchase of machinery and equipment for production		21.189.552.054	15.509.085.402		
Other activities		26.409.646.076	12.738.385.354		
Total	-	50.983.340.305	31.775.158.531		
5. Other short-term receivables					
		Ending balance of period	Beginning balance		
Uncollected personal income tax		-	-		
Other receivables		2.410.223.142	779.613.182		
Estimated interest on term deposits from the deposit date to 31st December		1.684.932	1.684.932		
Total	-	2.411.908.074	781.298.114		
6. Inventories					
		Ending balance of period	Beginning balance		
Materials and supplies		62.582.801.926	44.716.722.244		
Tools		740.061.754	687.319.418		
Work-in-process		4.554.130.657	-		
Finished goods		74.622.897.510	57.463.146.581		
Merchandises		418.477	1.062.920.469		
Total		142.500.310.324	103.930.108.712		
7. Increase / Decrease tangible fixed assets					
	Buildings and structures	Machineries and equipments	Vehicles	Tools management and other fixed assets	Total
Historical cost					
Beginning balance	33.321.724.375	221.326.508.533	21.312.809.053	13.219.657.137	289.180.699.098
Increase during period	-	19.927.465.966	-	531.674.000	20.459.139.966
New procurement		19.927.465.966		531.674.000	20.459.139.966
Completed construction	-	-	-	-	-

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Decrease during period	-	-	-	-	-
<i>Disposal, liquidation</i>					-
Ending balance of period	33.321.724.375	241.253.974.499	21.312.809.053	13.751.331.137	309.639.839.064
Depreciation					
Beginning balance	29.962.748.343	144.964.471.352	18.222.972.704	4.813.396.392	197.963.588.791
Increase during period	473.960.546	11.892.657.948	733.881.235	1.133.474.756	14.233.974.485
<i>Depreciation during year</i>	<i>473.960.546</i>	<i>11.892.657.948</i>	<i>733.881.235</i>	<i>1.133.474.756</i>	<i>14.233.974.485</i>
Decrease during period	-	-	-	-	-
<i>Disposal, liquidation</i>		-	-	-	-
<i>Others</i>					
Ending balance of period	30.436.708.889	156.857.129.300	18.956.853.939	5.946.871.148	212.197.563.276
Net book value					
Beginning balance	3.358.976.032	76.362.037.181	3.089.836.349	8.406.260.745	91.217.110.307
Ending balance of period	2.885.015.486	84.396.845.199	2.355.955.114	7.804.459.989	97.442.275.788

In which,

Historical cost of fully-depreciated tangible fixed assets is still in use 151.545.449.089 đồng

8. Increase / Decrease intangible fixed assets

	Land-use right	Computer software	Other intangible fixed assets	Total
Historical cost				
Beginning balance	2.916.105.767	3.849.899.609	1.291.759.533	8.057.764.909
Increase during period	-	13.530.000.000	-	13.530.000.000
<i>Procurement during period</i>	<i>-</i>	<i>13.530.000.000</i>	<i>-</i>	<i>13.530.000.000</i>
Decrease during period	-	-	-	-
Ending balance of period	2.916.105.767	17.379.899.609	1.291.759.533	21.587.764.909
Amortization				
Beginning balance	933.153.840	3.837.899.609	1.288.981.756	6.060.035.205
Increase during period	43.741.587	799.083.333	2.777.777	845.602.697
<i>Amortization during period</i>	<i>43.741.587</i>	<i>799.083.333</i>	<i>2.777.777</i>	<i>845.602.697</i>
Decrease during period	-	-	-	-
Ending balance of period	976.895.427	4.636.982.942	1.291.759.533	6.905.637.902
Net book value				
Beginning balance	1.982.951.927	12.000.000	2.777.777	1.997.729.704
Ending balance of period	1.939.210.340	12.742.916.667	-	14.682.127.007

In which,

Historical cost of fully-amortized intangible fixed assets is still in use 5.141.659.142 đồng

9. Short-term deferred costs

	Current year	Previous year
Insurance of all kinds	100.589.397	-
Tools and others	3.750.703.963	3.563.540.430
Total	3.851.293.360	3.563.540.430

10. Long-term deferred costs

Current year	Previous year
--------------	---------------

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Repair of fixed assets and tools	24.957.099.449	30.215.513.211		
Other long-term prepaid expenses	-	-		
Total	24.957.099.449	30.215.513.211		
11. Short-term finance lease loans and liabilities	314.890.146	-		
	Beginning balance	Loan amount arising	Loan amount already paid	Ending balance
Short-term loans from banks	181.005.840	127.832.185.204	(68.651.036.339)	59.362.154.705
Total	181.005.840	127.832.185.204	(68.651.036.339)	59.362.154.705
12. Trade payables				
	Current year	Previous year		
Purchase of raw materials for production	27.391.529.961	24.779.214.999		
Purchase of machinery and equipment for production	796.857.255	2.450.000.521		
Purchase of other supplies for production	993.683.886	1.305.709.049		
Total	29.182.071.102	28.534.924.569		
13. Advance payments from customers	-	-		
	Current year	Previous year		
Purchase of products	1.658.781.498	1.940.919.537		
Others	-	-		
Total	1.658.781.498	1.940.919.537		
14. Dividends and profits must be paid.	-	-		
	Current year	Previous year		
	14.071.759.618	15.240.981.474		
15. Taxes and Statutory obligations				
	Beginning balance	Payable during period	Already paid during period	Ending balance of period
Output Value added tax (VAT)	-	685.985.829	-	685.985.829
Value added tax (VAT) on imports	-	2.265.464.789	2.265.464.789	-
Corporate income tax (CIT)	7.559.671.718	14.693.655.758	15.559.671.718	6.693.655.758
Personal income tax (PIT)	505.670.070	3.388.223.350	2.774.322.494	1.119.570.926
Resource tax	322.560	2.434.320	2.477.520	279.360
License tax	-	-	-	-
Real estate tax, land rent	-	4.173.312.803	2.096.935.175	2.076.377.628
Charges, duties and others	-	70.000.000	70.000.000	-
Total	8.065.664.348	25.279.076.849	22.768.871.696	10.575.869.501
16. Other short-term payables	-	-		
	Current year	Previous year		
Social insurance, health insurance, unemployment insurance	169.987.117	-		
Short-term deposits and mortgages	615.000.000	351.000.000		
Dividends payable	14.071.759.618	15.240.981.474		
Selling expenses	199.958.320	198.864.502		
Others	2.980.000	11.576.943		
Total	15.059.685.055	15.802.422.919		
17. Bonus and welfare funds and Bonus fund for the Executive Management Board	-	-		
	Beginning balance	Increase from appropriation of profit	Decrease during period	Ending balance of period

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Bonus fund	6.972.362.656	9.130.739.884	(7.383.361.365)	8.719.741.175
Welfare fund	(547.627.486)	4.260.345.279	(5.049.666.600)	(1.336.948.807)
Bonus fund for the Executive Management Board (Remuneration fund of the Board of Management)	957.693.611	3.045.246.628	(3.421.328.334)	581.611.905
Total	7.382.428.781	16.436.331.791	(15.854.356.299)	7.964.404.273

18. Owners' equity

Bảng đối chiếu biến động của Vốn chủ sở hữu

Thông tin về biến động của vốn chủ sở hữu được trình bày trên Phụ lục đính kèm

Cổ phiếu

	Current year	Previous year
Number of stocks being registered to issue	9.332.573	9.332.573
Number of stocks already issued / public offering	9.332.573	9.332.573
- Common stocks	9.332.573	9.332.573
- Preferred stocks	-	-
Number of buy-back stocks	-	-
- Common stocks	-	-
- Preferred stocks	-	-
Number of outstanding stocks	9.332.573	9.332.573
- Common stocks	9.332.573	9.332.573
- Preferred stocks	-	-
Nominal value of outstanding stocks (VND/stock)	10.000	10.000

(**) Details of profit distribution are as follows:

Beginning balance		53.306.348.102
Increase from business results during period		58.519.323.033
Reconcile the development investment fund with undistributed profits		93.250.277.906
Decrease during period, including:		48.431.056.002
- Make appropriation of Bonus and welfare funds and remuneration of the Board of Management and Supervisory Board from profit	17.036.280.430	
- From profit 2025	2.815.280.430	
- From profit 2026	14.221.000.000	
Dividends paid to shareholders (in cash)	31.394.775.572	
- Supplementary payment for 2025	18.329.173.372	
- Dividend payment (2nd tranche) for 2025	13.065.602.200	
Ending balance of period as at 30th September /2026	-	156.644.893.039

VI ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE INCOME STATEMENTS

1. Revenues from sale of goods and rendering of services

	Accumulated from the beginning of year to the end of this quarter	
Total revenues	Current year	Previous year
- Sale of goods	681.670.291	6.103.714.996
- Sale of finished goods	409.071.753.411	379.380.055.023
In which: Export	-	-
Total	409.753.423.702	385.483.770.019

2. Revenue deductions

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

	Current year	Previous year
- Returned goods	9.235.080	-
- Returned finished products, trade discounts	6.463.518.119	1.041.489.722
Total	6.472.753.199	1.041.489.722
3. Net revenues	-	-
- Sale of goods	672.435.211	6.103.714.996
- Finished goods	402.608.235.292	378.338.565.301
<i>In which: Export</i>	-	-
Total	403.280.670.503	384.442.280.297
4. Cost of goods sold	-	-
	Current year	Previous year
Goods sold	465.012.876	4.115.375.437
Finished goods sold	226.352.188.959	216.029.034.117
Total	226.817.201.835	220.144.409.554
5. Income from financial activities	-	-
	Current year	Previous year
Interest on term deposits	249.863.015	3.793.855.878
Interest on call deposits	29.017.571	22.272.606
Interest on realized exchange rate differences	3.556	-
Interest on unrealized exchange rate differences	-	-
Total	278.884.142	3.816.128.484
6. Expenses from financial activities	-	-
	Current year	Previous year
Interest expense	3.522.918.855	302.465.753
Total	3.522.918.855	302.465.753
7. Selling expenses	-	-
	Current year	Previous year
Employee costs	24.978.745.905	27.013.696.392
<i>Wages and salary</i>	21.518.650.727	23.546.061.366
<i>Trade union's fees, Social insurance, health insurance, unemployment insurance</i>	2.357.329.178	2.703.812.526
<i>Mid-shift meal costs</i>	1.102.766.000	763.822.500
Raw materials, tools	2.093.183.410	934.364.840
Depreciation / Amortization of fixed assets	147.657.267	788.797.715
Outsourcing expenses	1.099.074.509	1.778.816.270
Others	24.953.188.444	11.977.325.809
Total	53.271.849.535	42.493.001.026
8. General & administration expenses	-	-
	Current year	Previous year
Employee costs	25.470.114.166	27.866.747.144
<i>Wages and salary</i>	23.311.871.623	25.508.233.148
<i>Trade union's fees, Social insurance, health insurance, unemployment insurance</i>	1.626.517.543	1.917.566.496
<i>Mid-shift meal costs</i>	531.725.000	440.947.500
Raw materials, management tools	3.848.759.279	573.467.608

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Depreciation / Amortization of fixed assets	1.572.834.478	224.632.216
Taxes and duties	2.616.029.582	2.622.529.582
Outsourcing expenses	6.843.693.387	5.830.080.300
Others	6.458.295.777	8.213.609.303
Total	46.809.726.669	45.331.066.153
9. Other income		
	Current year	Previous year
Sale of liquidated fixed assets		664.545.455
Sale of raw materials	4.500.800	23.662.514
Scrap sales and internship guiding practice for students	197.109.721	27.209.102
Total	201.610.521	715.417.071
10. Other expenses		
	Current year	Previous year
Sale of raw materials	3.920.868	22.820.802
Penalties for administrative violations and others	122.568.613	70.000.000
Total	126.489.481	92.820.802
11. Current Corporate income tax (CIT) expenses		
	Current year	Previous year
Total pre-tax accounting profit	73.212.978.791	80.610.062.564
- - Increase adjustments	255.300.000	225.900.000
Taxable income	73.468.278.791	80.835.962.564
Corporate income tax (CIT) rate	20%	20%
Current Corporate income tax (CIT) expenses payable	14.693.655.758	16.167.192.513
12. Gains on stock		
	Current year	Previous year
Accounting profit after corporate income tax	58.519.323.033	64.442.870.051
Profit or loss is allocated for shareholders holding common stock	58.519.323.033	64.442.870.051
Average outstanding common stock during year	9.332.573	9.332.573
Gains on stock (VND/stock)	4.577	5.041
13. Expenses from operating activities by nature		
	Current year	Previous year
Raw materials	155.008.648.354	159.898.566.390
Employee costs	111.484.547.067	112.557.532.886
<i>Wages and salary</i>	97.213.317.682	97.330.295.445
<i>Trade union's fees, Social insurance, health insurance, unemployment insurance</i>	10.016.405.385	11.904.739.941
<i>Mid-shift meal costs</i>	4.254.824.000	3.322.497.500
Tools	13.847.992.320	2.005.952.396
Depreciation / Amortization of fixed assets	15.035.835.595	8.273.581.070
Outsourcing expenses	18.780.097.381	18.103.785.599
Others	34.509.311.094	24.999.333.875
Total	348.666.431.811	325.838.752.216
VII. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE AGGREGATED STATEMENT OF CASH FLOW (Currency: VND)		
Loans to other entities and payments for purchase of debt instruments of other entities		

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

	Current year	Previous year
Tiền gửi có kỳ hạn tại các ngân hàng		
Term deposits at banks	500.000.000	500.000.000
Total	500.000.000	500.000.000

VIII. OTHER INFORMATION**1 Relationship with related parties**

Related parties	Relationship	Contributed capital ratio
Saigon Pharmaceutical Company Limited (SAPHARCO)	Affiliate company	43,44%
Tasco Biologicals and Pharmaceuticals Co., Ltd.	Major shareholder	24,37%

2 Transactions during period with related parties

(*) Members of key management are members of the Board of Management, the Board of Directors and Chief Accountant

Transactions with related parties

	Accumulated from the beginning of year to the end of this quarter	
	Current year	Previous year
Saigon Pharmaceutical Company Limited (SAPHARCO)		
Beginning balance	9.451.611.493	15.034.969.582
Sales of finished products	36.584.822.070	29.752.861.769
Proceeds from sale of finished products	35.360.083.010	37.814.002.449
Ending balance of period	10.676.350.553	6.973.828.902
HA NOI BRANCH		
Beginning balance	1.591.544.539	2.366.944.147
Sales of finished products	2.814.673.063	3.400.504.083
Proceeds from sale of finished products	3.636.683.191	4.963.566.236
Ending balance of period	769.534.411	803.881.994
DA NANG BRANCH		
Beginning balance		1.356.781.913
Sales of finished products	3.996.986.316	4.169.451.868
Proceeds from sale of finished products	3.252.148.045	5.006.730.629
Ending balance of period	744.838.271	519.503.152
NHA TRANG BRANCH		
Beginning balance	52.944.346	1.117.719.605
Sales of finished products	865.739.792	74.075.211
Proceeds from sale of finished products	889.694.340	26.211.306
Ending balance of period	28.989.798	1.165.583.510
CAN THO BRANCH		
Beginning balance	-	-
Sales of finished products	3.664.486.761	-
Proceeds from sale of finished products	3.314.746.150	-
Ending balance of period	349.740.611	-
RESANTIS BRANCH		
Beginning balance	926.200.800	-
Sales of finished products		-
Proceeds from sale of finished products	926.200.800	-
Ending balance of period	-	-
Tasco Biologicals and Pharmaceuticals Co., Ltd.		

PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Beginning balance	-	-
Sales of finished products	14.615.261.280	-
Proceeds from sale of finished products	8.340.500.827	-
Ending balance of period	6.274.760.453	-
Pharmedic Pharmaceutical Medicinal JSC - PHARMEDIC		
Beginning balance	-	-
Purchase of raw materials and goods		
Payment to SAPHARCO for purchase of raw materials and goods		4.317.932.788
Ending balance of period	-	(4.317.932.788)

All transactions with affiliated company as related parties are performed through economic contracts.

The selling price of products provided to related parties as well as the purchase price of raw materials from related parties are all made at market prices.

Accounts receivable are unsecured and will be paid in cash. Accounts receivable from related parties for which no provision has been made for doubtful debts.

Approve, 15th October 2026

Prepared by


 Trần Mạnh Hùng

Chief Accountant


 NGUYỄN ĐIỀU LÊ

General Director



PHARMEDIC PHARMACEUTICAL MEDICINAL JOINT STOCK COMPANY

Address: 367 Nguyen Trai street, Cau Ong Lanh ward, Ho Chi Minh city.

FINANCIAL STATEMENTS

For the nine-month period ended 30th September 2026

Appendix : The movement on the Owners' equity

	Owners' invested equity	Surplus of share capital	Development and investment funds	Undistributed earnings after tax (**)	Total
Beginning balance in previous year	93.325.730.000	972.972.000	93.250.277.906	102.062.842.363	289.611.822.269
Profit increase in previous year				82.304.932.561	82.304.932.561
Decrease in previous year				(131.061.426.822)	(131.061.426.822)
+ Make appropriation of funds				(22.168.965.058)	(22.168.965.058)
+ Dividend distribution			-	(108.892.461.764)	(108.892.461.764)
+ Other decrease				-	-
Ending balance in previous year, Beginning balance in current year	93.325.730.000	972.972.000	93.250.277.906	53.306.348.102	240.855.328.008
Profit increase in current year				151.769.600.939	151.769.600.939
+ Increase from business results				58.519.323.033	58.519.323.033
+ Reversal of development investment funds				93.250.277.906	93.250.277.906
Bonus shares			-		-
Decrease in current year			(93.250.277.906)	(48.431.056.002)	(141.681.333.908)
+ Reversal of development investment funds			(93.250.277.906)		(93.250.277.906)
+ Make appropriation of funds				(17.036.280.430)	(17.036.280.430)
+ Dividend distribution				(31.394.775.572)	(31.394.775.572)
+ Other decrease				-	-
Ending balance in current period	93.325.730.000	972.972.000	-	156.644.893.039	250.943.595.039

Prepared by

Trần Mạnh Hùng

Chief Accountant

Nguyễn Diệu Lê
NGUYỄN DIỆU LÊ

Approve, 15th October 2026

General Director



ĐS. LÊ VIỆT HÙNG